Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B
Background - The PENELOPE-B study demonstrated that the addition of 1-year post-neoadjuvant palbociclib to endocrine therapy (ET) in patients with high-risk early breast cancer (BC) did not improve invasive disease-free survival (iDFS) compared to placebo. Here, we report results for premenopausal w...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
June 2024
|
| In: |
ESMO open
Year: 2024, Volume: 9, Issue: 6, Pages: 1-10 |
| ISSN: | 2059-7029 |
| DOI: | 10.1016/j.esmoop.2024.103466 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.esmoop.2024.103466 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2059702924012353 
|
| Author Notes: | F. Marmé, M. Martin, M. Untch, C. Thode, H. Bonnefoi, S.-B. Kim, H. Bear, N. Mc Carthy, K. Gelmon, J.A. García-Sáenz, C.M. Kelly, T. Reimer, O. Valota, M. Toi, H.S. Rugo, M. Gnant, A. Makris, M. Bassy, Z. Zhang, J. Furlanetto, V. Nekljudova & S. Loibl |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1915639980 | ||
| 003 | DE-627 | ||
| 005 | 20250716224401.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250127s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.esmoop.2024.103466 |2 doi | |
| 035 | |a (DE-627)1915639980 | ||
| 035 | |a (DE-599)KXP1915639980 | ||
| 035 | |a (OCoLC)1528017571 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Marmé, Frederik |d 1974- |e VerfasserIn |0 (DE-588)132561972 |0 (DE-627)52394893X |0 (DE-576)299226549 |4 aut | |
| 245 | 1 | 0 | |a Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy |b subgroup analyses of premenopausal patients in PENELOPE-B |c F. Marmé, M. Martin, M. Untch, C. Thode, H. Bonnefoi, S.-B. Kim, H. Bear, N. Mc Carthy, K. Gelmon, J.A. García-Sáenz, C.M. Kelly, T. Reimer, O. Valota, M. Toi, H.S. Rugo, M. Gnant, A. Makris, M. Bassy, Z. Zhang, J. Furlanetto, V. Nekljudova & S. Loibl |
| 264 | 1 | |c June 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 4. Juni 2024, Artikelversion: 4. Juni 2024 | ||
| 500 | |a Gesehen am 27.01.2025 | ||
| 520 | |a Background - The PENELOPE-B study demonstrated that the addition of 1-year post-neoadjuvant palbociclib to endocrine therapy (ET) in patients with high-risk early breast cancer (BC) did not improve invasive disease-free survival (iDFS) compared to placebo. Here, we report results for premenopausal women. - Patients and methods - Patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative BC at high risk of relapse [defined as no pathological complete response after neoadjuvant chemotherapy and a clinical, pathological stage, estrogen receptor, grading (CPS-EG) score ≥3 or 2/ypN+] were randomized to receive 13 cycles of palbociclib or placebo + standard ET. Ovarian function (OF) was evaluated by centrally assessed estradiol, follicle-stimulating hormone and anti-Müllerian hormone serum levels. - Results - Overall, 616 of 1250 randomized patients were premenopausal; of these, 30.0% were <40 years of age, 47.4% had four or more metastatic lymph nodes, and 58.2% had a CPS-EG score ≥3. 66.1% of patients were treated with tamoxifen alone, and 32.9% received ovarian function suppression (OFS) in addition to either tamoxifen or aromatase inhibitor (AI). After a median follow-up of 42.8 months (97.2% completeness) no difference in iDFS between palbociclib and placebo was observed [hazard ratio = 0.95, 95% confidence interval (CI) 0.69-1.30, P = 0.737]. The estimated 3-year iDFS rate was marginally higher in the palbociclib arm (80.6% versus 78.3%). Three year iDFS was higher in patients receiving AI than tamoxifen plus OFS or tamoxifen alone (86.0% versus 78.6% versus 78.0%). Patients receiving tamoxifen plus OFS showed a favorable iDFS with palbociclib (83.0% versus 74.1%, hazard ratio = 0.52, 95% CI 0.27-1.02, P = 0.057). Hematologic adverse events were more frequent with palbociclib (76.1% versus 1.9% grade 3-4, P < 0.001). Palbociclib seems not to negatively impact the OF throughout the treatment period. - Conclusions - In premenopausal women, who received tamoxifen plus OFS as ET, the addition of palbociclib to ET results in a favorable iDFS. The safety profile seems favorable and in contrast to chemotherapy palbociclib does not impact OF throughout the treatment period. | ||
| 650 | 4 | |a adjuvant CDK4/6 inhibitor | |
| 650 | 4 | |a early breast cancer | |
| 650 | 4 | |a HER2 negative | |
| 650 | 4 | |a hormone receptor positive | |
| 650 | 4 | |a ovarian function | |
| 650 | 4 | |a palbociclib | |
| 650 | 4 | |a PENELOPE-B | |
| 650 | 4 | |a premenopausal | |
| 700 | 1 | |a Martin, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Untch, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Thode, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bonnefoi, H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kim, S. -B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bear, H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mc Carthy, N. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gelmon, K. |e VerfasserIn |4 aut | |
| 700 | 1 | |a García-Sáenz, J. A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kelly, C. M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reimer, T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Valota, O. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Toi, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rugo, H. S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gnant, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Makris, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bassy, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zhang, Z. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Furlanetto, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nekljudova, V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Loibl, S. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ESMO open |d [London] : Elsevier, 2016 |g 9(2024), 6, Artikel-ID 103466, Seite 1-10 |h Online-Ressource |w (DE-627)84705344X |w (DE-600)2844985-X |w (DE-576)454658516 |x 2059-7029 |7 nnas |a Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy subgroup analyses of premenopausal patients in PENELOPE-B |
| 773 | 1 | 8 | |g volume:9 |g year:2024 |g number:6 |g elocationid:103466 |g pages:1-10 |g extent:10 |a Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy subgroup analyses of premenopausal patients in PENELOPE-B |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.esmoop.2024.103466 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S2059702924012353 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250127 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 132561972 |a Marmé, Frederik |m 132561972:Marmé, Frederik |d 60000 |d 61300 |d 50000 |e 60000PM132561972 |e 61300PM132561972 |e 50000PM132561972 |k 0/60000/ |k 1/60000/61300/ |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1915639980 |e 4656560197 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"person":[{"given":"Frederik","role":"aut","family":"Marmé","display":"Marmé, Frederik"},{"given":"M.","role":"aut","family":"Martin","display":"Martin, M."},{"family":"Untch","display":"Untch, M.","given":"M.","role":"aut"},{"family":"Thode","display":"Thode, C.","role":"aut","given":"C."},{"role":"aut","given":"H.","display":"Bonnefoi, H.","family":"Bonnefoi"},{"given":"S. -B.","role":"aut","family":"Kim","display":"Kim, S. -B."},{"family":"Bear","display":"Bear, H.","role":"aut","given":"H."},{"role":"aut","given":"N.","family":"Mc Carthy","display":"Mc Carthy, N."},{"given":"K.","role":"aut","family":"Gelmon","display":"Gelmon, K."},{"role":"aut","given":"J. A.","display":"García-Sáenz, J. A.","family":"García-Sáenz"},{"display":"Kelly, C. M.","family":"Kelly","role":"aut","given":"C. M."},{"family":"Reimer","display":"Reimer, T.","role":"aut","given":"T."},{"role":"aut","given":"O.","display":"Valota, O.","family":"Valota"},{"display":"Toi, M.","family":"Toi","given":"M.","role":"aut"},{"given":"H. S.","role":"aut","family":"Rugo","display":"Rugo, H. S."},{"role":"aut","given":"M.","display":"Gnant, M.","family":"Gnant"},{"role":"aut","given":"A.","display":"Makris, A.","family":"Makris"},{"display":"Bassy, M.","family":"Bassy","given":"M.","role":"aut"},{"role":"aut","given":"Z.","display":"Zhang, Z.","family":"Zhang"},{"given":"J.","role":"aut","family":"Furlanetto","display":"Furlanetto, J."},{"display":"Nekljudova, V.","family":"Nekljudova","role":"aut","given":"V."},{"given":"S.","role":"aut","family":"Loibl","display":"Loibl, S."}],"id":{"doi":["10.1016/j.esmoop.2024.103466"],"eki":["1915639980"]},"physDesc":[{"extent":"10 S.","noteIll":"Illustrationen"}],"name":{"displayForm":["F. Marmé, M. Martin, M. Untch, C. Thode, H. Bonnefoi, S.-B. Kim, H. Bear, N. Mc Carthy, K. Gelmon, J.A. García-Sáenz, C.M. Kelly, T. Reimer, O. Valota, M. Toi, H.S. Rugo, M. Gnant, A. Makris, M. Bassy, Z. Zhang, J. Furlanetto, V. Nekljudova & S. Loibl"]},"relHost":[{"recId":"84705344X","physDesc":[{"extent":"Online-Ressource"}],"name":{"displayForm":["European Society for Medical Oncology"]},"id":{"zdb":["2844985-X"],"issn":["2059-7029"],"eki":["84705344X"]},"title":[{"title":"ESMO open","subtitle":"cancer horizons","title_sort":"ESMO open"}],"pubHistory":["1.2016 -"],"origin":[{"publisherPlace":"[London] ; London","dateIssuedDisp":"2016-","publisher":"Elsevier ; BMJ","dateIssuedKey":"2016"}],"note":["Gesehen am 13.06.24"],"disp":"Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy subgroup analyses of premenopausal patients in PENELOPE-BESMO open","type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"part":{"extent":"10","volume":"9","year":"2024","pages":"1-10","text":"9(2024), 6, Artikel-ID 103466, Seite 1-10","issue":"6"},"corporate":[{"role":"isb","display":"European Society for Medical Oncology"}]}],"recId":"1915639980","type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title_sort":"Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy","subtitle":"subgroup analyses of premenopausal patients in PENELOPE-B","title":"Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy"}],"note":["Online veröffentlicht: 4. Juni 2024, Artikelversion: 4. Juni 2024","Gesehen am 27.01.2025"],"origin":[{"dateIssuedDisp":"June 2024","dateIssuedKey":"2024"}]} | ||
| SRT | |a MARMEFREDEPALBOCICLI2024 | ||